Disrupted copper availability in sporadic ALS: implications for Cu II (atsm) as a treatment option
That means by now, all compounding pharmacies are technically required to stop making these drugs
Patent WO2016025382 (2014)
Tiered Pricing Options: Provide different service levels, such as basic (GLP-1 only) and premium (GLP-1 + nutritional coaching, lab tests, or personalized plans)
These anecdotal reports, which constitute low-level evidence, have gained considerable attention on social media platforms and in patient communities, prompting scientific investigation into whether these observations represent a genuine pharmacologic effect or coincidental behavioral changes associated with improved metabolic health and weight loss
But there IS a lot of hype floating around this stack, and most of it comes from people who dont understand the underlying pharmacology or how to properly dose and cycle either compound